Nalaganje...
Rucaparib and Niraparib in Advanced Ovarian Cancer
Rucaparib and niraparib are two of the newest U.S. Food and Drug Administration–approved PARP inhibitors, joining olaparib with indications in ovarian cancer. Both drugs have led to meaningful responses when used as monotherapy in previously treated ovarian cancers, with niraparib demonstrating acti...
Shranjeno v:
| izdano v: | J Adv Pract Oncol |
|---|---|
| Glavni avtor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Harborside Press LLC
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7520743/ https://ncbi.nlm.nih.gov/pubmed/33343988 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6004/jadpro.2019.10.4.8 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|